Summary
4EBS Chart
Emergent Biosolutions Q2 Earnings Call Highlights
Emergent Biosolutions NYSE: EBS reported second-quarter 2026 revenue and adjusted EBITDA above its prior guidance and analyst consensus, driven by accelerated medical countermeasure deliveries to U.S. government customers. The company also lowered its full-year outlook as increased competition and pricing pressure in the naloxone market are expected to weigh on sales of NARCAN.
Emergent BioSolutions Inc. (EBS) Q2 2026 Earnings Call Transcript
Emergent BioSolutions Inc. (EBS) Q2 2026 Earnings Call Transcript
Emergent BioSolutions Inc. (EBS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
Emergent BioSolutions Inc. (EBS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Prepared Remarks Transcript
ERSTE GROUP BANK (4EBS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has ERSTE GROUP BANK ever had a stock split?
ERSTE GROUP BANK Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Joseph C. Papa Jr. CEO | XMIL Exchange | US29089Q1058 ISIN |
| US Country | 900 Employees | - Last Dividend | - Last Split | 15 Nov 2006 IPO Date |
Overview
Emergent BioSolutions Inc. is a life sciences company that specializes in offering preparedness and response solutions against a range of public health threats, including accidental, deliberate, and naturally occurring ones, within the United States. With its foundation dating back to 1998, the company is based in Gaithersburg, Maryland. Emergent BioSolutions Inc. is dedicated to safeguarding public health through its comprehensive portfolio of products designed to combat serious health threats such as opioid overdose, cholera, typhoid fever, anthrax, smallpox, Ebola, and exposure to various chemical and biological warfare agents. In addition to its product offerings, Emergent BioSolutions Inc. extends its expertise through contract development and manufacturing services, emphasizing drug substance and product manufacturing, packaging, technology transfer, and process and analytical development.
Products and Services
- NARCAN Nasal Spray: Emergency treatment for known or suspected opioid overdose.
- Vaxchora vaccine: Prevents cholera.
- Vivotif vaccine: An oral vaccine for the prevention of typhoid fever.
- Anthrasil: Treats inhalational anthrax.
- BioThrax: An anthrax vaccine.
- CYFENDUS: Post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis.
- Raxibacumab injection: For the treatment and prophylaxis of inhalational anthrax.
- ACAM2000: A smallpox vaccine.
- CNJ-016: Addresses complications from smallpox vaccination.
- TEMBEXA: Treats smallpox disease caused by variola virus in adults and pediatric patients.
- BAT: Treats symptomatic botulism.
- Ebanga: Treats Ebola.
- Reactive Skin Decontamination Lotion Kit: Removes or neutralizes chemical warfare agents from the skin.
- Trobigard: An atropine sulfate obidoxime chloride auto-injector for chemical warfare agent poisoning.
- Products under development: Including CGRD-001 for treatment of poisoning by organophosphorus nerve agents, EBS-LASV for Lassa fever prevention, EBS-MARV to prevent Marburg virus disease, and several other vital projects focused on combating infectious diseases and chemical agent exposures.
- Contract Development and Manufacturing Services: Offers drug substance and product manufacturing, packaging, technology transfer, process, and analytical development services tailored to clients' specific needs.
